New insights into mechanisms of atrial fibrillation.

Although atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice, precise mechanisms that lead to the onset and persistence of AF have not completely been elucidated. Over the last decade, outstanding progress has been made in understanding the complex pathophysiology of AF. The key role of ectopic foci in pulmonary veins as a trigger of AF has been recognized. Furthermore, structural remodeling was identified as the main mechanism for AF persistence, confirming predominant role of atrial fibrosis. Systemic inflammatory state, oxidative stress injury, autonomic balance and neurohormonal activation were discerned as important modifiers that affect AF susceptibility. This new understanding of AF pathophysiology has led to the emergence of novel therapies. Ablative interventions, renin-angiotensin system blockade, modulation of oxidative stress and targeting tissue fibrosis represent new approaches in tackling AF. This review aims to provide a brief summary of novel insights into AF mechanisms and consequent therapeutic strategies.

[1]  A. G. Gittenberger-de Groot,et al.  The role of neural crest and epicardium-derived cells in conduction system formation. , 2003, Novartis Foundation symposium.

[2]  S. Nattel,et al.  Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing–Induced Congestive Heart Failure , 2001, Circulation.

[3]  Robert H. Anderson,et al.  Anatomy of the Left Atrium: , 1999, Journal of cardiovascular electrophysiology.

[4]  J. Goudevenos,et al.  Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. , 2005, International journal of cardiology.

[5]  G Hindricks,et al.  Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease , 2004, Heart.

[6]  Thomas H Everett,et al.  Atrial fibrosis and the mechanisms of atrial fibrillation. , 2007, Heart rhythm.

[7]  A. Tveit,et al.  Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. , 2007, The American journal of cardiology.

[8]  M. Allessie,et al.  Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation , 1985 .

[9]  A. Takeshita,et al.  Role of Transforming Growth Factor-β1 in Cardiovascular Inflammatory Changes Induced by Chronic Inhibition of Nitric Oxide Synthesis , 2000 .

[10]  M. Allessie,et al.  Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation? , 2005, Heart rhythm.

[11]  Sander Verheule,et al.  Arrhythmogenic Substrate of the Pulmonary Veins Assessed by High-Resolution Optical Mapping , 2003, Circulation.

[12]  A. Takeshita,et al.  Transforming Growth Factor- (cid:1) Function Blocking Prevents Myocardial Fibrosis and Diastolic Dysfunction in Pressure-Overloaded Rats , 2002 .

[13]  A. Takeshita,et al.  Role of transforming growth factor-beta1 in cardiovascular inflammatory changes induced by chronic inhibition of nitric oxide synthesis. , 2000, Hypertension.

[14]  H. Thaler,et al.  Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. , 2005, Chest.

[15]  Javier Moreno,et al.  Activation of Inward Rectifier Potassium Channels Accelerates Atrial Fibrillation in Humans: Evidence for a Reentrant Mechanism , 2006, Circulation.

[16]  A. L. Wit,et al.  Triggered activity and atrial fibrillation. , 2007, Heart rhythm.

[17]  S. Nattel,et al.  Effects of Antiarrhythmic Drugs on Fibrillation in the Remodeled Atrium: Insights Into the Mechanism of the Superior Efficacy of Amiodarone , 2003, Circulation.

[18]  K. Becker,et al.  Gene expression profiling of oxidative stress on atrial fibrillation in humans , 2003, Experimental & Molecular Medicine.

[19]  S Nattel,et al.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. , 1999, Circulation.

[20]  D. Zipes,et al.  Effects of selective vagal and stellate ganglion stimulation of atrial refractoriness. , 1974, Cardiovascular research.

[21]  J. Towbin Scarring in the heart--a reversible phenomenon? , 2007, The New England journal of medicine.

[22]  T. Hewitson,et al.  Drugs of the future: the hormone relaxin , 2007, Cellular and Molecular Life Sciences.

[23]  D. Levy,et al.  Pulse pressure and risk of new-onset atrial fibrillation. , 2007, JAMA.

[24]  K. Stangl,et al.  Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. , 2000, Journal of the American College of Cardiology.

[25]  D. V. Van Wagoner,et al.  Impaired Myofibrillar Energetics and Oxidative Injury During Human Atrial Fibrillation , 2001, Circulation.

[26]  Samuel Wann,et al.  [Guidelines for the management of patients with atrial fibrillation. Executive summary]. , 2006, Revista espanola de cardiologia.

[27]  W. Stevenson,et al.  Atrial Fibrillation after Cardiac Surgery , 2001, Annals of Internal Medicine.

[28]  L. Katwa,et al.  Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. , 1997, Journal of molecular and cellular cardiology.

[29]  Bruce M Psaty,et al.  Inflammation as a Risk Factor for Atrial Fibrillation , 2003, Circulation.

[30]  S Nattel,et al.  Tachycardia-induced changes in Na+ current in a chronic dog model of atrial fibrillation. , 1997, Circulation research.

[31]  Stanley Nattel,et al.  Mechanisms of atrial fibrillation: lessons from animal models. , 2005, Progress in cardiovascular diseases.

[32]  M. Fishbein,et al.  Nerve sprouting induced by radiofrequency catheter ablation in dogs. , 2004, Heart rhythm.

[33]  Liming Zhang,et al.  Cellular electrophysiology of canine pulmonary vein cardiomyocytes: action potential and ionic current properties , 2003, The Journal of physiology.

[34]  Douglas L. Jones,et al.  Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. , 1995, Circulation.

[35]  M. Russo,et al.  Histological substrate of atrial biopsies in patients with lone atrial fibrillation. , 1997, Circulation.

[36]  Mitsuru Yamamoto,et al.  Pacing-Induced Spontaneous Activity in Myocardial Sleeves of Pulmonary Veins After Treatment With Ryanodine , 2003, Circulation.

[37]  T. Doetschman,et al.  TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II , 2002 .

[38]  P. Box Corticosteroids for the prevention of atrial fibrillation after cardiac surgery:A randomized controlled trial , 2007 .

[39]  J Clémenty,et al.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. , 1998, The New England journal of medicine.

[40]  E. Gang,et al.  Radiofrequency catheter ablation and nerve growth factor concentration in humans. , 2006, Heart rhythm.

[41]  J. Keaney Oxidative stress and the vascular wall: NADPH oxidases take center stage. , 2005, Circulation.

[42]  Sebastian Wachsmann-Hogiu,et al.  Autonomic innervation and segmental muscular disconnections at the human pulmonary vein-atrial junction: implications for catheter ablation of atrial-pulmonary vein junction. , 2006, Journal of the American College of Cardiology.

[43]  W. Evans,et al.  LONE AURICULAR FIBRILLATION , 1954, British heart journal.

[44]  K. Nademanee,et al.  A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. , 2004, Journal of the American College of Cardiology.

[45]  W. Rheinboldt,et al.  A COMPUTER MODEL OF ATRIAL FIBRILLATION. , 1964, American heart journal.

[46]  R. Sheppard,et al.  Fibrosis in heart disease: understanding the role of transforming growth factor‐β1 in cardiomyopathy, valvular disease and arrhythmia , 2006, Immunology.

[47]  N. Mochizuki,et al.  Angiotensin II Type 1 Receptor Blocker Prevents Atrial Structural Remodeling in Rats with Hypertension Induced by Chronic Nitric Oxide Inhibition , 2006, Hypertension Research.

[48]  M. Allessie,et al.  Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. , 1997, Circulation.

[49]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[50]  Steven V. Ley,et al.  Targeting C-reactive protein for the treatment of cardiovascular disease , 2006, Nature.

[51]  E. Fleck,et al.  Angiotensin II directly increases transforming growth factor beta1 and osteopontin and indirectly affects collagen mRNA expression in the human heart. , 2000, Cardiovascular research.

[52]  C. White,et al.  The Impact of Suppressing the Renin‐Angiotensin System on Atrial Fibrillation , 2006, Journal of clinical pharmacology.

[53]  M. Di Nisio,et al.  Increased Expression of Transforming Growth Factor-β1 as a Stabilizing Factor in Human Atherosclerotic Plaques , 2004, Stroke.

[54]  K. Channon,et al.  A Myocardial Nox2 Containing NAD(P)H Oxidase Contributes to Oxidative Stress in Human Atrial Fibrillation , 2003, Circulation research.

[55]  Ralph Lazzara,et al.  Autonomically induced conversion of pulmonary vein focal firing into atrial fibrillation. , 2005, Journal of the American College of Cardiology.

[56]  C. Hack,et al.  Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. , 1997, Circulation.

[57]  C. Pandozi,et al.  Electrophysiological characteristics of the human atria after cardioversion of persistent atrial fibrillation. , 1998, Circulation.

[58]  J. Olgin,et al.  Pirfenidone Prevents the Development of a Vulnerable Substrate for Atrial Fibrillation in a Canine Model of Heart Failure , 2006, Circulation.

[59]  J. Dernellis,et al.  Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. , 2004, European heart journal.

[60]  S. Nattel,et al.  Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. , 2007, Cardiovascular research.

[61]  M. Chung,et al.  Ascorbate Attenuates Atrial Pacing-Induced Peroxynitrite Formation and Electrical Remodeling and Decreases the Incidence of Postoperative Atrial Fibrillation , 2001, Circulation research.

[62]  D. Hopkins,et al.  Gross and microscopic anatomy of the human intrinsic cardiac nervous system , 1997, The Anatomical record.

[63]  Sander Verheule,et al.  Increased Vulnerability to Atrial Fibrillation in Transgenic Mice With Selective Atrial Fibrosis Caused by Overexpression of TGF-β1 , 2004, Circulation research.

[64]  S Nattel,et al.  Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. , 1999, Cardiovascular research.

[65]  H. Wellens,et al.  Philippe Coumel: a founding father of modern arrhythmology. , 2004, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[66]  S. Nattel,et al.  Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. , 2003, Cardiovascular research.

[67]  M. Fishbein,et al.  Nonreentrant focal activations in pulmonary veins in canine model of sustained atrial fibrillation. , 2002, American journal of physiology. Heart and circulatory physiology.

[68]  Shokei Kim,et al.  Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. , 1995, The Journal of pharmacology and experimental therapeutics.

[69]  José Jalife,et al.  Reentry and atrial fibrillation. , 2007, Heart rhythm.

[70]  M. Allessie,et al.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. , 1995, Circulation.

[71]  CarloPappone,et al.  Pulmonary Vein Denervation Enhances Long-Term Benefit After Circumferential Ablation for Paroxysmal Atrial Fibrillation , 2004 .

[72]  S. Nattel,et al.  Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. , 2006, Cardiovascular research.

[73]  T. Doetschman,et al.  TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. , 2002, The Journal of clinical investigation.

[74]  Nassir F Marrouche,et al.  Vagal denervation and atrial fibrillation inducibility: epicardial fat pad ablation does not have long-term effects. , 2006, Heart rhythm.

[75]  A. Hsueh,et al.  Activation of Orphan Receptors by the Hormone Relaxin , 2002, Science.

[76]  U Schotten,et al.  “Early” Class III Drugs for the Treatment of Atrial Fibrillation: Efficacy and Atrial Selectivity of AVE0118 in Remodeled Atria of the Goat , 2004, Circulation.

[77]  A. Becker How structurally normal are human atria in patients with atrial fibrillation? , 2004, Heart rhythm.

[78]  S Nattel,et al.  Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. , 1997, Circulation research.

[79]  S. Mohiuddin,et al.  Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. , 2006, American heart journal.